Lyra Therapeutics Beat Consensus Estimates

Lyra Therapeutics (LYRA) reported a loss of $5.51 per share on revenue of $0.18 million for the second quarter ended June 2025. The consensus estimate was a loss of $5.79 per share on revenue of $0.15 million. The company beat consensus estimates by 4.84% while revenue fell 69.40% compared to the same quarter a year ago.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases. The company’s lead product candidate, LYR-210, is designed to deliver up to six months of continuous anti-inflammatory drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS) in patients who have not undergone surgery for the disease. Lyra is also developing LYR-220 for CRS patients who have undergone a prior surgery and have persistent disease.